JP2013510868A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510868A5 JP2013510868A5 JP2012538994A JP2012538994A JP2013510868A5 JP 2013510868 A5 JP2013510868 A5 JP 2013510868A5 JP 2012538994 A JP2012538994 A JP 2012538994A JP 2012538994 A JP2012538994 A JP 2012538994A JP 2013510868 A5 JP2013510868 A5 JP 2013510868A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- agent
- group
- binding protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26114909P | 2009-11-13 | 2009-11-13 | |
| US61/261,149 | 2009-11-13 | ||
| PCT/US2010/056430 WO2011060206A2 (en) | 2009-11-13 | 2010-11-12 | Material and methods for treating or preventing her-3 associated diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000552A Division JP6235620B2 (ja) | 2009-11-13 | 2016-01-05 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510868A JP2013510868A (ja) | 2013-03-28 |
| JP2013510868A5 true JP2013510868A5 (https=) | 2014-02-13 |
| JP5931736B2 JP5931736B2 (ja) | 2016-06-08 |
Family
ID=43618172
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538994A Active JP5931736B2 (ja) | 2009-11-13 | 2010-11-12 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2016000552A Active JP6235620B2 (ja) | 2009-11-13 | 2016-01-05 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2017206911A Pending JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2019172295A Active JP7317650B2 (ja) | 2009-11-13 | 2019-09-20 | Ｈｅｒ－３関連疾患を治療または予防するための物質および方法 |
| JP2021152652A Pending JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016000552A Active JP6235620B2 (ja) | 2009-11-13 | 2016-01-05 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2017206911A Pending JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2019172295A Active JP7317650B2 (ja) | 2009-11-13 | 2019-09-20 | Ｈｅｒ－３関連疾患を治療または予防するための物質および方法 |
| JP2021152652A Pending JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9101760B2 (https=) |
| EP (5) | EP3670539A1 (https=) |
| JP (5) | JP5931736B2 (https=) |
| KR (1) | KR101806323B1 (https=) |
| CN (2) | CN105999263B (https=) |
| AR (1) | AR080564A1 (https=) |
| AU (1) | AU2010319483B2 (https=) |
| BR (1) | BR112012012160B1 (https=) |
| CA (1) | CA2780935C (https=) |
| CY (2) | CY1119751T1 (https=) |
| DK (2) | DK2719708T3 (https=) |
| ES (3) | ES2781299T3 (https=) |
| HK (1) | HK1207651A1 (https=) |
| HR (2) | HRP20180104T1 (https=) |
| HU (2) | HUE049880T2 (https=) |
| LT (2) | LT3351558T (https=) |
| MX (3) | MX358013B (https=) |
| NO (1) | NO2719708T3 (https=) |
| PL (2) | PL2719708T3 (https=) |
| PT (2) | PT3351558T (https=) |
| RS (2) | RS56741B1 (https=) |
| SI (2) | SI3351558T1 (https=) |
| SM (2) | SMT202000267T1 (https=) |
| TW (1) | TWI630916B (https=) |
| UY (1) | UY33034A (https=) |
| WO (1) | WO2011060206A2 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2364495T3 (es) | 2005-02-03 | 2011-09-05 | The General Hospital Corporation | Método para tratar cáncer resistente a gefitinib. |
| JP2009514870A (ja) | 2005-11-04 | 2009-04-09 | ワイス | ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2692769T3 (es) | 2008-06-17 | 2018-12-05 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| CN105147713A (zh) | 2008-08-04 | 2015-12-16 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| BRPI0920209A2 (pt) | 2008-10-15 | 2015-12-22 | Angiochem Inc | conjugados de agonistas de glp-1 e usos dos mesmos |
| CN104447995A (zh) * | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| SG174382A1 (en) | 2009-04-06 | 2011-11-28 | Wyeth Llc | Treatment regimen utilizing neratinib for breast cancer |
| US8916574B2 (en) | 2009-09-28 | 2014-12-23 | Qilu Pharmaceutical Co., Ltd. | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| EP2494046B1 (en) | 2009-10-30 | 2018-09-12 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
| AU2015201262B2 (en) * | 2009-11-13 | 2017-04-27 | Amgen Inc. | Material and methods for treating or preventing her-3 associated diseases |
| MX358013B (es) * | 2009-11-13 | 2018-08-01 | Amgen Inc | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. |
| MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| CN107903321A (zh) | 2010-07-30 | 2018-04-13 | 诺华有限公司 | 纤连蛋白摇篮分子和其库 |
| NZ607337A (en) | 2010-08-20 | 2015-06-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| JP6033783B2 (ja) | 2010-11-01 | 2016-11-30 | シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ | Ｐａｎ−ｈｅｒ抗体組成物 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| HK1200468A1 (en) | 2011-09-30 | 2015-08-07 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| EP2773659A2 (en) | 2011-10-31 | 2014-09-10 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
| JP6180425B2 (ja) | 2011-11-23 | 2017-08-23 | メディミューン，エルエルシー | Ｈｅｒ３に特異的な結合分子及びそれらの使用 |
| AU2012349735B2 (en) * | 2011-12-05 | 2016-05-19 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| EA201491120A1 (ru) * | 2011-12-05 | 2015-07-30 | Новартис Аг | Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3 |
| EP2817335A1 (en) * | 2012-02-22 | 2014-12-31 | U3 Pharma GmbH | Combination of hb-egf binding protein and egfr inhibitor |
| ES2842201T3 (es) * | 2012-02-23 | 2021-07-13 | Daiichi Sankyo Europe Gmbh | Inhibidor de HER3 para modulación de radiosensibilidad |
| EP2844675B1 (en) * | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| EP2885321A4 (en) * | 2012-08-14 | 2016-03-30 | Angiochem Inc | CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
| EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
| US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| US20160213760A1 (en) * | 2012-11-12 | 2016-07-28 | Angiochem Inc. | Aprotinin-derived polypeptide-antibody conjugates |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| KR102399277B1 (ko) * | 2014-04-10 | 2022-05-18 | 다이이찌 산쿄 가부시키가이샤 | 항her3 항체-약물 콘주게이트 |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| CA2959716A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| AU2015313811A1 (en) | 2014-09-08 | 2017-04-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) |
| CN104861068B (zh) * | 2015-01-23 | 2020-11-17 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗her3抗体及其治疗相关疾病的用途 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
| EP4180455A1 (en) | 2015-06-29 | 2023-05-17 | Daiichi Sankyo Company, Limited | Method for selectively manufacturing antibody-drug conjugate |
| WO2017102789A1 (en) * | 2015-12-17 | 2017-06-22 | F. Hoffmann-La Roche Ag | Combination therapy of anti-her3 antibodies and anti-her2 antibodies |
| CN110167968B (zh) | 2016-09-15 | 2023-11-28 | 斯图加特大学 | 针对her3的抗原结合蛋白 |
| BR112019011794A2 (pt) | 2016-12-12 | 2019-10-29 | Daiichi Sankyo Co Ltd | composição farmacêutica, e, método terapêutico. |
| CA3050668C (en) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate |
| KR20240074000A (ko) * | 2017-02-28 | 2024-05-27 | 다이이찌 산쿄 가부시키가이샤 | 항 her3 항체-약물 콘주게이트 투여에 의한 egfr-tki 저항성의 비소세포 폐암의 치료 방법 |
| CA3060407A1 (en) * | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| TW202532102A (zh) | 2017-05-15 | 2025-08-16 | 日商第一三共股份有限公司 | 抗體－藥物結合物及其用途 |
| BR112020003466B1 (pt) | 2017-08-31 | 2023-12-12 | Daiichi Sankyo Company, Limited | Métodos de produção de composto, e, composto |
| ES3057444T3 (en) | 2017-08-31 | 2026-03-02 | Daiichi Sankyo Co Ltd | Improved method for producing antibody-drug conjugate |
| HUE067382T2 (hu) | 2018-05-18 | 2024-10-28 | Daiichi Sankyo Co Ltd | Anti-MUC1-exatecan antitest-hatóanyag konjugátum |
| JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗ｈｅｒ３抗体およびその用途 |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| TW202537643A (zh) | 2018-07-31 | 2025-10-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之用途 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| JP2023512214A (ja) | 2020-01-28 | 2023-03-24 | リフレクション メディカル， インコーポレイテッド | 放射性核種および外部ビーム放射線療法の共同最適化 |
| AU2023228226A1 (en) * | 2022-03-03 | 2024-10-03 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Her3 binding protein and use thereof |
| EP4514396A1 (en) * | 2022-04-29 | 2025-03-05 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Antibody-drug conjugates and preparation methods and use thereof |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1467383A (en) | 1974-06-12 | 1977-03-16 | Farmaceutici Italia | Daunomycin analogues |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4471052A (en) | 1982-01-18 | 1984-09-11 | Adria Laboratories, Inc. | Biosynthesis of simplified anthracyclines |
| JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US4939168A (en) | 1989-08-11 | 1990-07-03 | Harbor Branch Oceanographics Institution, Inc. | Discodermolide compounds, compositions containing same and methods of preparation and use |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| AU2235992A (en) | 1991-06-14 | 1993-01-12 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| JPH07508410A (ja) | 1992-06-18 | 1995-09-21 | ジェンファーム インターナショナル インコーポレイテッド | 酵母人工染色体を有するトランスジェニック非ヒト動物の製造方法 |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| AU697142B2 (en) * | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
| FR2718135B1 (fr) | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Procédé de préparation d'hydroxy-7 taxanes. |
| FR2721928A1 (fr) | 1994-07-04 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5643763A (en) | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| TW321649B (https=) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| US5837815A (en) * | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
| WO1997007671A1 (en) | 1995-08-29 | 1997-03-06 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for constructing the same |
| US5681847A (en) | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
| IL126303A (en) | 1996-03-27 | 2002-05-23 | Genentech Inc | ErbB3 ANTIBODIES |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6114595A (en) * | 1996-04-11 | 2000-09-05 | The Procter & Gamble Company | Stretchable, extensible composite topsheet for absorbent articles |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| ATE271603T1 (de) | 1996-12-11 | 2004-08-15 | Sugen Inc | Identifizierungsverfahren für substanzen die an das pyk2 polypeptid binden |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| NZ511722A (en) | 1998-11-20 | 2004-05-28 | Kosan Biosciences Inc | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| AU2209899A (en) | 1998-12-30 | 2000-07-24 | Sugen, Inc. | Pyk2 (raftk) and inflammation |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| CA2376596C (en) | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| TR200200472T2 (tr) | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
| FR2817258B1 (fr) * | 2000-11-27 | 2003-01-10 | Atofina | Procede de sulfochloration photochimique d'alcanes gazeux |
| IL152420A0 (en) | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| US7718387B2 (en) | 2001-09-20 | 2010-05-18 | Board Of Regents, The University Of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
| US7435871B2 (en) | 2001-11-30 | 2008-10-14 | Amgen Fremont Inc. | Transgenic animals bearing human Igλ light chain genes |
| AU2002357779A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Identification of high affinity molecules by limited dilution screening |
| CN1219882C (zh) | 2002-03-18 | 2005-09-21 | 上海泽生科技开发有限公司 | 以erbb－3为基础的用于肿瘤治疗的方法和组合物 |
| EP2400021B1 (en) | 2002-03-26 | 2016-11-30 | Zensun (Shanghai) Science & Technology, Co., Ltd. | ErbB3 based methods and compositions for treating neoplasms |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| JP4443407B2 (ja) | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ， インコーポレイテッド | レセプターオリゴマー形成の検出 |
| DE60333228D1 (de) | 2002-12-02 | 2010-08-12 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| CA2521077A1 (en) | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Erbb surface receptor complexes as biomarkers |
| JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
| CA2592177A1 (en) * | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| US7557182B2 (en) | 2005-02-18 | 2009-07-07 | Angiochem Inc. | Molecules for transporting a compound across the blood-brain barrier |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| EP1931798A1 (en) * | 2005-10-05 | 2008-06-18 | AstraZeneca UK Limited | Method to predict or monitor the response of a patient to an erbb receptor drug |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| SG178789A1 (en) * | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
| PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| JP5752687B2 (ja) * | 2009-08-21 | 2015-07-22 | メリマック ファーマシューティカルズ インコーポレーティッド | Ｅｒｂｂ３の外部ドメインに対する抗体およびその使用 |
| MX358013B (es) * | 2009-11-13 | 2018-08-01 | Amgen Inc | Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3. |
| AU2018396083B2 (en) | 2017-12-29 | 2025-09-25 | Cellectis | Method for improving production of CAR T cells |
-
2010
- 2010-11-12 MX MX2016008205A patent/MX358013B/es unknown
- 2010-11-12 PT PT171977119T patent/PT3351558T/pt unknown
- 2010-11-12 CA CA2780935A patent/CA2780935C/en active Active
- 2010-11-12 SM SM20200267T patent/SMT202000267T1/it unknown
- 2010-11-12 EP EP20151640.8A patent/EP3670539A1/en active Pending
- 2010-11-12 PL PL13189092T patent/PL2719708T3/pl unknown
- 2010-11-12 SM SM20180167T patent/SMT201800167T1/it unknown
- 2010-11-12 HU HUE17197711A patent/HUE049880T2/hu unknown
- 2010-11-12 NO NO13189092A patent/NO2719708T3/no unknown
- 2010-11-12 WO PCT/US2010/056430 patent/WO2011060206A2/en not_active Ceased
- 2010-11-12 BR BR112012012160-0A patent/BR112012012160B1/pt active IP Right Grant
- 2010-11-12 EP EP15154165.3A patent/EP2896632B1/en active Active
- 2010-11-12 SI SI201032011T patent/SI3351558T1/sl unknown
- 2010-11-12 EP EP13189092.3A patent/EP2719708B1/en active Active
- 2010-11-12 CN CN201610373755.5A patent/CN105999263B/zh active Active
- 2010-11-12 PL PL17197711T patent/PL3351558T3/pl unknown
- 2010-11-12 PT PT131890923T patent/PT2719708T/pt unknown
- 2010-11-12 LT LTEP17197711.9T patent/LT3351558T/lt unknown
- 2010-11-12 MX MX2016002120A patent/MX357972B/es unknown
- 2010-11-12 ES ES17197711T patent/ES2781299T3/es active Active
- 2010-11-12 HU HUE13189092A patent/HUE035605T2/en unknown
- 2010-11-12 RS RS20180048A patent/RS56741B1/sr unknown
- 2010-11-12 MX MX2012005589A patent/MX349513B/es active IP Right Grant
- 2010-11-12 KR KR1020127015255A patent/KR101806323B1/ko active Active
- 2010-11-12 DK DK13189092.3T patent/DK2719708T3/da active
- 2010-11-12 LT LTEP13189092.3T patent/LT2719708T/lt unknown
- 2010-11-12 RS RS20200651A patent/RS60390B1/sr unknown
- 2010-11-12 AU AU2010319483A patent/AU2010319483B2/en active Active
- 2010-11-12 ES ES15154165.3T patent/ES2647466T3/es active Active
- 2010-11-12 TW TW099139038A patent/TWI630916B/zh active
- 2010-11-12 SI SI201031627T patent/SI2719708T1/en unknown
- 2010-11-12 US US12/944,764 patent/US9101760B2/en active Active
- 2010-11-12 ES ES13189092.3T patent/ES2655737T3/es active Active
- 2010-11-12 DK DK17197711.9T patent/DK3351558T3/da active
- 2010-11-12 EP EP17197711.9A patent/EP3351558B1/en active Active
- 2010-11-12 EP EP10785251A patent/EP2499162A2/en not_active Withdrawn
- 2010-11-12 JP JP2012538994A patent/JP5931736B2/ja active Active
- 2010-11-12 CN CN201080052236.XA patent/CN102812045B/zh active Active
- 2010-11-15 AR ARP100104211 patent/AR080564A1/es unknown
- 2010-11-15 UY UY33034A patent/UY33034A/es not_active Application Discontinuation
-
2013
- 2013-04-25 US US13/870,796 patent/US9803025B2/en active Active
-
2015
- 2015-08-20 HK HK15108089.8A patent/HK1207651A1/en unknown
-
2016
- 2016-01-05 JP JP2016000552A patent/JP6235620B2/ja active Active
- 2016-01-18 US US15/000,005 patent/US9988462B2/en active Active
-
2017
- 2017-10-26 JP JP2017206911A patent/JP2018076300A/ja active Pending
- 2017-10-27 US US15/796,361 patent/US12139549B2/en active Active
- 2017-12-13 CY CY20171101305T patent/CY1119751T1/el unknown
-
2018
- 2018-01-19 HR HRP20180104TT patent/HRP20180104T1/hr unknown
-
2019
- 2019-09-20 JP JP2019172295A patent/JP7317650B2/ja active Active
-
2020
- 2020-06-05 CY CY20201100505T patent/CY1123030T1/el unknown
- 2020-06-08 HR HRP20200921TT patent/HRP20200921T1/hr unknown
-
2021
- 2021-09-17 JP JP2021152652A patent/JP2022000445A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510868A5 (https=) | ||
| HRP20200921T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 | |
| JP2020011980A5 (https=) | ||
| US7598350B2 (en) | Human anti-epidermal growth factor receptor antibody | |
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| RU2013136172A (ru) | Белки, связывающие антиген фактор роста, подобный гепаринсвязывающему эпидермальному фактору роста | |
| JP2021059564A (ja) | 癌治療のための併用療法 | |
| JP2017529838A5 (https=) | ||
| JP2020516240A5 (https=) | ||
| JP2021531764A5 (https=) | ||
| JP2008531576A5 (https=) | ||
| RU2010123888A (ru) | Axl-антитела | |
| JP2017519759A5 (https=) | ||
| JP2011046732A5 (https=) | ||
| HRP20240626T1 (hr) | Bispecifična antitijela protiv ceacam5 i cd3 | |
| JP2017514795A5 (https=) | ||
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| JP2013520442A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2009544574A5 (https=) | ||
| CN114450025A (zh) | 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症 | |
| JP2015518824A5 (https=) | ||
| JP6989645B2 (ja) | ＥｒｂＢ３に特異的に結合する抗体、及びその用途 | |
| JPWO2023161943A5 (https=) |